What is it about?
This article—a mixed-methods study conducted between May 2018 and May 2019 in Indonesia, Kyrgyzstan, and Nigeria—explores how acceptable, practical, and ready health systems are to adopt the six-month oral BPaL regimen (bedaquiline + pretomanid + linezolid) for treating extensively drug-resistant tuberculosis (XDR-TB).
Featured Image
Photo by Melany @ tuinfosalud.com on Unsplash
Why is it important?
This study is important because it helps bridge the gap between scientific innovation and on-the-ground implementation—which is often where life-saving health solutions fail. It tells us not just that BPaL works, but that people and systems are ready—or can be ready—to use it to fight one of the toughest forms of tuberculosis.
Perspectives
Most stakeholders are optimistic and supportive, viewing BPaL as a game changer. However, the succesMost stakeholders are optimistic and supportive, viewing BPaL as a game changer. However, the successful implementation depends on strengthening health systems, ensuring regulatory readiness, and training personnel to monitor safety effectively.
Dr. Bakyt Bolotbekovich Myrzaliev
KNCV Tuberculosefonds
Read the Original
This page is a summary of: Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients, BMC Public Health, July 2021, Springer Science + Business Media,
DOI: 10.1186/s12889-021-11427-y.
You can read the full text:
Contributors
The following have contributed to this page
